ENVERIC BIOSCIENCES INC
ENVBNASDAQ🏆 #3720 by market capUS Equity
$1.54▲ $0.00 (+0.00%)
Live1h—
24h▲ 0.0%
7d▼ 9.9%
14d▲ 16.7%
30d▲ 14.1%
1y▼ 88.1%
🏦Market Cap
$6M
Small Cap
📈Revenue Growth (YoY)
-7.2%
Declining
📊Gross Margin
20.4%
Moderate
💵FCF Margin
0.4%
Thin
⚖️P/S Ratio
0.1x
Cheap
Otter Score
48
Weak
Trading Snapshot
- Day Range
- $1.52 – $1.56
- 52-Week Range
- $1.25 – $17.64
- Volume
- $1.92B
- Avg Volume
- $1.98B
- Shares Outstanding
- 3.7M
- Next Earnings
- Sep 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $40M
- Last Q Revenue
- $9M
- P/E Ratio
- —
- P/S Ratio
- 0.1x
- EPS (TTM)
- $-22.04
- Dividend Yield
- —
Why Investors Own ENVB
- ✓High-growth profile — revenue up +35.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$40M▲ +31.7% YoY
Gross Margin (TTM)
38.5%▲ +0.6% YoY
Operating Income (TTM)
$14M▲ +31.7% YoY
Free Cash Flow (TTM)
$8M▲ +31.7% YoY
About ENVERIC BIOSCIENCES INC
A company profile for ENVERIC BIOSCIENCES INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
48/100
Analyst Price Target
ⓘAverage Target
$1.97
▲ +27.7% Upside
High Target$2.16
Low Target$1.56
Based on 10 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
ENVERIC BIOSCIENCES INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift ENVB price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
ENVERIC BIOSCIENCES INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.